(PACS) PACS - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 5.975m USD | Total Return: 280.3% in 12m
Avg Turnover: 29.7M
Qual. Beats: 1
Rev. Trend: 100.0%
Warnings
Altman Z'' 0.77 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Rs Leader, Idiosyncratic Leader, Confidence
PACS Group, Inc. is a healthcare real estate and operations firm focused on skilled nursing, assisted living, and independent living facilities across the United States. Founded in 2013, the company employs a vertically integrated model that combines property ownership and leasing with direct clinical care management.
The skilled nursing sector operates within a highly regulated environment where revenue is largely driven by federal Medicare and state Medicaid reimbursement rates. Companies in this sub-industry often utilize a hub-and-spoke geographic strategy to optimize staffing and supply chain costs across regional clusters.
Investors can evaluate the company’s specific valuation metrics and historical performance trends on ValueRay. PACS Group remains headquartered in Salt Lake City, Utah, maintaining a diversified portfolio of healthcare-related properties.
- Strategic acquisitions of underperforming skilled nursing facilities drive inorganic revenue growth
- Medicare and Medicaid reimbursement rate adjustments dictate core operating margins
- Labor cost inflation and nursing shortages impact facility level profitability
- Federal regulatory changes regarding minimum staffing mandates increase compliance expenses
- Occupancy rate recovery across post-acute care portfolios accelerates organic cash flow
| Net Income: 243.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.85 > 1.0 |
| NWC/Revenue: -0.10% < 20% (prev -0.58%; Δ 0.48% < -1%) |
| CFO/TA 0.09 > 3% & CFO 490.3m > Net Income 243.8m |
| Net Debt (2.85b) to EBITDA (442.5m): 6.44 < 3 |
| Current Ratio: 0.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (162.1m) vs 12m ago 4.45% < -2% |
| Gross Margin: 17.46% > 18% (prev 0.13%; Δ 1.73k% > 0.5%) |
| Asset Turnover: 97.37% > 50% (prev 81.78%; Δ 15.59% > 0%) |
| Interest Coverage Ratio: 13.68 > 6 (EBITDA TTM 442.5m / Interest Expense TTM 27.9m) |
| A: -0.00 (Total Current Assets 1.07b - Total Current Liabilities 1.07b) / Total Assets 5.66b |
| B: 0.07 (Retained Earnings 390.3m / Total Assets 5.66b) |
| C: 0.07 (EBIT TTM 381.5m / Avg Total Assets 5.58b) |
| D: 0.08 (Book Value of Equity 390.4m / Total Liabilities 4.62b) |
| Altman-Z'' = 0.77 = B |
| DSRI: 0.89 (Receivables 733.2m/680.7m, Revenue 5.43b/4.49b) |
| GMI: 0.75 (GM 17.46% / 13.18%) |
| AQI: 1.09 (AQ_t 0.07 / AQ_t-1 0.06) |
| SGI: 1.21 (Revenue 5.43b / 4.49b) |
| TATA: -0.04 (NI 243.8m - CFO 490.3m) / TA 5.66b) |
| Beneish M = -3.18 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 38.87 with a total of 669,402 shares traded.
Over the past week, the price has changed by +5.60%,
over one month by +10.21%,
over three months by -6.72% and
over the past year by +280.33%.
PACS has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy PACS.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 49.2 | 26.5% |
P/E Trailing = 24.3548
P/E Forward = 16.6667
P/S = 1.0999
P/B = 5.7607
P/EG = 1.1111
Revenue TTM = 5.43b USD
EBIT TTM = 381.5m USD
EBITDA TTM = 442.5m USD
Long Term Debt = 284.8m USD (from longTermDebt, last quarter)
Short Term Debt = 162.7m USD (from shortTermDebt, last quarter)
Debt = 3.10b USD (from shortLongTermDebtTotal, last quarter) (leases 3.07b already included)
Net Debt = 2.85b USD (calculated: Debt 3.10b - CCE 248.0m)
Enterprise Value = 8.82b USD (5.97b + Debt 3.10b - CCE 248.0m)
Interest Coverage Ratio = 13.68 (Ebit TTM 381.5m / Interest Expense TTM 27.9m)
EV/FCF = 37.22x (Enterprise Value 8.82b / FCF TTM 237.0m)
FCF Yield = 2.69% (FCF TTM 237.0m / Enterprise Value 8.82b)
FCF Margin = 4.36% (FCF TTM 237.0m / Revenue TTM 5.43b)
Net Margin = 4.49% (Net Income TTM 243.8m / Revenue TTM 5.43b)
Gross Margin = 17.46% ((Revenue TTM 5.43b - Cost of Revenue TTM 4.48b) / Revenue TTM)
Gross Margin QoQ = 16.36% (prev 16.46%)
Tobins Q-Ratio = 1.56 (Enterprise Value 8.82b / Total Assets 5.66b)
Interest Expense / Debt = 0.90% (Interest Expense 27.9m / Debt 3.10b)
Taxrate = 29.07% (33.1m / 113.7m)
NOPAT = 270.6m (EBIT 381.5m * (1 - 29.07%))
Current Ratio = 0.99 (Total Current Assets 1.07b / Total Current Liabilities 1.07b)
Debt / Equity = 2.99 (Debt 3.10b / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = 6.44 (Net Debt 2.85b / EBITDA 442.5m)
Debt / FCF = 12.01 (Net Debt 2.85b / FCF TTM 237.0m)
Total Stockholder Equity = 915.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.37% (Net Income 243.8m / Total Assets 5.66b)
RoE = 26.63% (Net Income TTM 243.8m / Total Stockholder Equity 915.5m)
RoCE = 31.78% (EBIT 381.5m / Capital Employed (Equity 915.5m + L.T.Debt 284.8m))
RoIC = 5.72% (NOPAT 270.6m / Invested Capital 4.73b)
WACC = 6.79% (E(5.97b)/V(9.07b) * Re(9.97%) + D(3.10b)/V(9.07b) * Rd(0.90%) * (1-Tc(0.29)))
Discount Rate = 9.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.41 | Cagr: 131.0%
[DCF] Terminal Value 73.22% ; FCFF base≈252.9m ; Y1≈223.2m ; Y5≈182.7m
[DCF] Fair Price = 0.50 (EV 2.93b - Net Debt 2.85b = Equity 79.2m / Shares 158.3m; r=8.35% [WACC [floored]]; 5y FCF grow -14.35% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.45 | # QB: 1
Revenue Correlation: 99.98 | Revenue CAGR: 30.38% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.56 | Chg30d=+3.07% | Revisions=+33% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.56 | Chg30d=-1.33% | Revisions=-14% | Analysts=4
EPS current Year (2026-12-31): EPS=2.37 | Chg30d=+12.51% | Revisions=+43% | GrowthEPS=+30.8% | GrowthRev=+8.4%
EPS next Year (2027-12-31): EPS=2.51 | Chg30d=+6.34% | Revisions=+14% | GrowthEPS=+6.1% | GrowthRev=+6.8%
[Analyst] Revisions Ratio: +43%